Background--The failure of cholesteryl ester transfer protein inhibitor torcetrapib was associated with an off-target increase in plasma aldosterone. We sought to evaluate the impact of evacetrapib on plasma aldosterone level and determine the association between plasma aldosterone level and major adverse cardiovascular events among patients with stable high-risk vascular disease enrolled in the ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes) trial.
T he cholesteryl transfer protein (CETP) inhibitors were a much anticipated drug class that were shown in earlyphase studies to significantly increase serum high-density lipoprotein (HDL) while lowering low-density lipoprotein.
Despite this, they failed to show a reduction in cardiovascular events in several recent randomized controlled trials. [1] [2] [3] [4] The reasons for this remain unclear, with possible mechanisms including an adverse effect of CETP inhibition, such as generation of dysfunctional or proatherogenic HDL cholesterol, or off-target drug effects. Specifically, torcetrapib was associated with an increase in plasma aldosterone levels that was presumed to be its mechanism of failure. 1 The mechanism by which CETP inhibition may increase aldosterone levels is unknown, with suggestion that it might stimulate aldosterone production within adipocytes. 5 Whether the failure of the potent CETP inhibitor evacetrapib was also associated with an increase in plasma aldosterone levels remains unclear. Aldosterone, a mineralocorticoid hormone, has been linked to the development of ventricular remodeling and tissue fibrosis in animal models and elevated plasma levels have been associated with adverse clinical outcomes among patients with acute coronary syndromes and chronic heart failure. [6] [7] [8] [9] [10] [11] In addition, several randomized controlled trials have demonstrated a mortality benefit with the use of aldosterone antagonists in patients with acute myocardial infarction and ejection fraction <40%, with possibly some benefit among those with an acute coronary syndrome and preserved ejection fraction. [12] [13] [14] [15] The association between plasma aldosterone level and outcomes in patients with stable high-risk vascular disease has not been previously evaluated. The ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes) trial was a multicenter, randomized, double-blinded, placebo-controlled trial at 543 sites in 36 countries investigating the use of evacetrapib on patients with stable high-risk vascular disease. 3 We sought to evaluate the impact of evacetrapib on plasma aldosterone levels and determine the association between plasma aldosterone levels and major adverse cardiovascular events (MACEs) among patients with stable high-risk vascular disease.
Methods
The authors declare that all supporting data are available within the article and its online supplementary files. The study protocol was approved by the Cleveland Clinic Foundation institutional review board; need for informed consent was waived.
The design of the ACCELERATE trial has previously been described. 16 Briefly, %12 000 patients with stable high-risk vascular disease, including those with previous acute coronary syndrome, peripheral arterial disease, cerebrovascular disease, and diabetes mellitus with known history of coronary artery disease, were randomized in a 1:1 manner to evacetrapib, 130 mg, versus placebo. The trial was event driven, with a primary end point of MACE, which included cardiovascular death, myocardial infarction, cerebrovascular accident, coronary revascularization, or hospitalization for unstable angina. Because of clinical futility for the primary composite end point, the trial was terminated prematurely after accrual of 1363 of the planned 1670 primary end point events and a median of 26 months study drug therapy. End of study visit was completed by 98.8% of patients. End points were identified and prospectively adjudicated by an independent clinical end points committee blinded to treatment assignment. The aldosterone substudy was restricted to ACCELERATE trial sites enrolling patients in the United States. The study collected samples from 1624 patients enrolled at 79 clinical sites. Serum samples were collected using a 3.5 serumseparating tube, locally spun, placed in a plain tube, frozen (À20°C) on site, and transferred to a central laboratory. Aldosterone was measured using a liquid chromatographytandem mass spectrometry method on the AB Sciex by QLab. A follow-up aldosterone level was similarly drawn at 12 months. No patients were excluded. We determined the impact of evacetrapib exposure compared with placebo on plasma aldosterone levels after 12 months of exposure. Baseline patient characteristics, medications, and laboratory data were summarized across quartiles of plasma aldosterone level as percentages for categorical variables and meansAESDs or medians and 25th and 75th percentiles for continuous variables. Categorical variables were compared using the v 2 test, whereas continuous variables were analyzed using the Student t test or the Mann-Whitney U test, when appropriate. Kaplan-Meier methods were used to estimate risk of end point for each quartile of baseline and percentage change in plasma aldosterone. Time to event was defined as the time from randomization to the onset of the end point. When used as a continuous measurement, plasma aldosterone was natural log transformed because of its nonnormal distribution. Hazard ratios with 95% CIs for the risk of end point with increasing quartile of baseline plasma aldosterone
Clinical Perspective
What Is New?
• Exposure to torcetrapib was associated with an off-target increase in plasma aldosterone levels, which was presumed to be its mechanism of failure.
• The failure of evacetrapib was not associated with an increase in plasma aldosterone.
• Among patients with stable high-risk vascular disease, plasma aldosterone does not predict future cardiovascular events.
What Are the Clinical Implications?
• This is an important mechanistic study that may be relevant to future clinical trials that investigate cholesteryl transfer protein inhibitors or use plasma aldosterone levels for risk stratification and patient selection.
level and percentage change in plasma aldosterone level at follow-up were calculated using Cox proportional hazards models. Multivariable regression was also performed, adjusting for potential confounders of MACE. Stepwise selection methods were used to determine significant predictors of MACE; variables with a P<0.05 remained in the final model. These variables included sex, peripheral arterial disease, prior percutaneous coronary intervention, current smoking, baseline CRP (C-reactive protein) and low-density lipoprotein, angiotensin-converting enzyme inhibitor or angiotensin receptor II antagonist use, and baseline systolic blood pressure. P≤0.05 was considered statistically significant. All analyses were performed using SAS System, version 9.4 (SAS Institute, Cary, NC).
Results
Among 12 092 patients enrolled in the ACCELERATE trial, 1624 had a plasma aldosterone level drawn at baseline; of these patients, 1554 also had a level drawn at 12-month were hypertensive, 73.3% were diabetic, 17.3% had metabolic syndrome, 57.6% had a prior myocardial infarction, 17.5% had peripheral arterial disease, and 14.6% were current tobacco users. At baseline, 94.3% of patients were taking a statin, 76.0% were taking an angiotensin-converting enzyme inhibitor or angiotensin receptor II antagonist, and 88.3% were taking aspirin. Baseline low-density lipoprotein cholesterol was 81.7 mg/dL, HDL cholesterol was 43.4 mg/dL, and triglycerides were 151.8 mg/dL. Increasing quartile of baseline plasma aldosterone level was significantly associated with a lower prevalence of men, lower systolic blood pressure, less use of angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist, and greater triglyceride levels at baseline; there were no other significant differences in baseline characteristics (Table 1 ). There were no significant differences in baseline characteristics of patients randomized to placebo or evacetrapib or the study population in comparison to the overall ACCELERATE trial population (Tables S1 through S6 (Figure 1 ). During follow-up, MACE occurred in 263 patients (16.2%), with all-cause mortality occurring in 78 patients (4.8%). The hazard ratio for the log of baseline plasma aldosterone level (hazard ratio, 1.03; 95% CI, 0.90-1.19; P=0.66; Figure 2 ) or percentage change in plasma aldosterone level at follow-up was not significant for MACE or subcomponents of MACE, including the triple end point (cardiovascular death (Tables 2 and 3 ). These findings remained consistent when adjusting for the significant baseline characteristics mentioned above (hazard ratio of the log of baseline plasma aldosterone for MACE, 1.01; 95% CI, 0.85-1.20; P=0.91) and when analyzing only the placebo group.
Discussion
Despite substantial improvements in both low-density lipoprotein cholesterol and HDL cholesterol lipid profiles, evacetrapib had essentially no effect on the frequency of cardiovascular events in comparison to placebo. The reasons for the failure of evacetrapib have remained unclear. Possible considerations include off-target adverse effects, such as an increase in aldosterone and blood pressure, as demonstrated by torcetrapib, 1 or on-target adverse effects, including production of dysfunctional or larger HDL cholesterol cholesterol-rich particles, 17, 18 an increase in blood viscosity, 19 or an increase in apolipoprotein CIII and E levels, 20, 21 which have been associated with increased cardiovascular risk. Albeit of questionable clinical relevance, both systolic blood pressure (1.2 mm Hg) and diastolic blood pressure (0.4 mm Hg) were significantly increased among patients randomized to use of evacetrapib in the ACCELERATE trial. However, we demonstrate that this difference was not associated with an increase in plasma aldosterone level at follow-up attributable to evacetrapib exposure. In the current data set, baseline and percentage change in plasma aldosterone levels at follow-up were not associated with an increased risk for cardiovascular events. Aldosterone has been linked to the development of ventricular remodeling and tissue fibrosis in animal models. 6 It has also been implicated to have a directly deleterious effect on blood vessels, as mediated by vascular and perivascular inflammation. 22 In the FOS (Framingham Offspring Study), normotensive patients with plasma aldosterone levels at the upper limit of normal were at high risk for subsequent development of hypertension. 23 In addition, patients with primary aldosteronism have been shown to have a greater rate of cardiovascular disease than age-matched controls with hypertension, suggesting a mechanism of disease progression that is independent of blood pressure. 24, 25 Moreover, aldosterone has also been associated with insulin resistance and the development of metabolic syndrome in both patients with obesity and primary aldosteronism. 26, 27 However, although there have been several previously published reports detailing an association between plasma aldosterone levels and cardiovascular events and mortality, [6] [7] [8] [9] [10] [11] the mechanism implicating aldosterone remains ambiguous. The populations from which these data arise are composed of patients in varied degrees of decompensated states and chronic illness (namely, acute coronary syndromes and heart failure). In these conditions, it is unclear as to whether plasma aldosterone has a directly deleterious effect or is rather a marker of excess reninangiotensin system activation, catecholamine surges, and hemodynamic decompensation. The association between plasma aldosterone level and outcomes in patients with stable high-risk vascular disease has not been previously studied and in our study was not shown to have an association. Our findings are consistent with those reported with a less potent CETP inhibitor, dalcetrapib, among patients with a recent acute coronary syndrome. 28 An important limitation of this study is lack of data on the number, dosage, and type of antihypertensive agents, with the exception of angiotensin-converting enzyme inhibitors or angiotensin receptor II antagonists. We also did not have use data on mineralocorticoid receptor antagonists. This is an important mechanistic study that may be relevant to future clinical trials that investigate CETP inhibitors or use plasma aldosterone levels for risk stratification and patient selection. Future studies on the utility of plasma aldosterone in prediction of cardiovascular events in clinically stable patients with risk factors for vascular disease are needed.
Conclusions
Exposure to evacetrapib did not result in significant change in plasma aldosterone levels compared with placebo. Among patients with high-risk vascular disease, plasma aldosterone level was not a predictor for cardiovascular events.
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